| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $46.1M | — | +49.3% |
| SG&A Expense | $11.2M | — | +22.2% |
| Operating Income | -$57.3M | — | -43.1% |
| Net Income | -$56.7M | — | -44.4% |
| EPS (Basic) | -$0.52 | — | +11.9% |
| EPS (Diluted) | -$0.52 | — | +11.9% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $297.1M | +396.0% | +41.1% |
| Current Assets | $396.8M | +93.1% | +26.6% |
| Total Assets | $422.9M | +81.9% | +23.0% |
| Current Liabilities | $30.3M | -9.5% | +5.2% |
| Total Liabilities | $48.8M | -7.2% | -1.4% |
| Stockholders' Equity | $374.1M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$47.2M | — | -48.3% |
| Capital Expenditures | $165K | — | +31.0% |
| Investing Cash Flow | $44.8M | — | +263.0% |
| Financing Cash Flow | $239.0M | — | +26.0% |
| Free Cash Flow | -$47.4M | — | -48.2% |
| +27.1% |